Merck & Company Inc (MRK)vsSepterna, Inc. Common Stock (SEPN)
MRK
Merck & Company Inc
$120.79
-2.77%
HEALTHCARE · Cap: $285.64B
SEPN
Septerna, Inc. Common Stock
$31.15
-0.70%
HEALTHCARE · Cap: $1.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 90922% more annual revenue ($65.77B vs $72.25M). MRK leads profitability with a 13.6% profit margin vs -49.9%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
SEPN
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Intrinsic value data unavailable for SEPN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Revenue surging 12011.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -9.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : SEPN
The strongest argument for SEPN centers on Revenue Growth, Debt/Equity. Revenue growth of 12011.0% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : SEPN
The primary concerns for SEPN are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while SEPN is a hypergrowth play — different risk/reward profiles.
SEPN is growing revenue faster at 12011.0% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (50/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Septerna, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Septerna, Inc. is a pioneering biotechnology firm dedicated to advancing transformative therapeutics through selective protein modulation. The company harnesses proprietary technologies and unparalleled scientific expertise to develop a promising pipeline of next-generation drug candidates aimed at addressing unmet medical needs across various disease areas. With a strong emphasis on research and development, Septerna is strategically positioned for growth, presenting a compelling investment opportunity for institutional investors in the rapidly evolving biopharmaceutical landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?